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ess: z.diamant@gems.dSummary Asthma is a chronic disorder, characterized by airway hyperresponsive-
ness (AHR), airway inflammation and airway remodelling. Evidence has been
provided for a relationship between pathophysiology, airway inflammation and
remodelling. Moreover, these asthma features have been shown to respond to anti-
inflammatory therapy. According to current guidelines, monitoring of asthma is
predominantly based on symptoms and lung function data. However, these
parameters appeared as poor indices for asthma control. Alternatively, asthma
control relates well to exacerbations and (anamnestic) surrogate biomarkers of
airway inflammation. Hence, appropriate treatment of asthma should primarily
target the airway inflammation.
According to current guidelines for asthma management, anti-inflammatory
therapy with inhaled corticosteroids (ICS) is the cornerstone in the treatment of
persistent asthma. To further optimize asthma control, add-on therapy with long-
acting b2-agonists (LABA) or leukotriene receptor antagonists (LTRA) should be
combined with low to high doses of ICS. While the first combination focuses on
optimal control of symptoms and lung function, the second provides a more
complete suppression of the airway inflammation.
In this paper we discuss treatment of asthma according to current guidelines
versus new insights, addressing practical issues.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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The hallmark of asthma comprises chronic airway
inflammation affecting both the large and the small
airways.1 Airway inflammation induces increased
‘twitchiness’ of the airways to various (a) specific
stimuli, the so-called airway hyperresponsiveness
(AHR), which subsequently causes the signs and
symptoms of asthma.2 Apart from this chronic
inflammatory process, there are structural changes
throughout the entire airway wall and beyond
found already early in asthma. This process is
termed ‘airway remodelling’ and currently there is
a dilemma going on whether it is a protective or
rather a detrimental process within the airways
(Fig. 1).3,4Treatment of asthma according to
current guidelines versus new insights
Practical issues
According to current guidelines, monitoring of
asthma is predominantly based on symptoms and
lung function data.5,6 However, these parameters
appeared poor indices for asthma control.7,8 Alter-
natively, asthma control has been shown to be
related to exacerbations and surrogate biomarkers
of inflammation.8,9 A recent study comparing two
management strategies in patients with mild-to-
moderate persistent asthma for 12 months, showed
that treatment aimed at controlling the airway
inflammation yielded better asthma control redu-
cing the frequency of severe exacerbations over
65% as compared with treatment aimed at improv-
ing symptoms and lung function only.9 As compared
with the reference group, the sputum eosinophil
counts and the exhaled NO were significantly
reduced and corresponded with an increasedAirway inflammation Airway remodelling
Bronchial hyperresponsiveness
Worsening of asthma control
Exacerbations
Figure 1 Relationship between the key features of
asthma.PC20(methacholine) in the sputum management
group.9 Interestingly, although patients in both
treatment groups had similar asthma characteris-
tics, superior asthma control in the sputum
management group was achieved at similar inhaled
corticosteroids (ICS) doses.9 These findings are in
keeping with previous observations by Sont
and colleagues comparing a treatment strategy
aimed at improving AHR strategy with the refer-
ence strategy aimed at improving symptoms and
lung function in patients with mild-to-moderate
persistent asthma for 24 months.8 As compared
with the reference strategy-treated patients, those
treated according to the AHR strategy had sig-
nificantly lower exacerbation rates corresponding
with reduced eosinophil numbers in bronchial
biopsies.8
What are the consequences of the new insights
for general practice? In general practice, only a few
workers can afford the time and investment of
measuring markers of airway inflammation, includ-
ing exhaled nitric oxide (eNO), sputum eosinophils,
or a methacholine/histamine PC20 for the assess-
ment of AHR for monitoring their patients’ asthma.
However, there are various anamnestic indices of a
worsening asthma control suggestive of increased
airway inflammation, often not spontaneously
brought up by patients, which may provide a useful
and reliable alternative (Table 1).10 These ‘ana-
mnestic surrogate markers of airway inflammation’
can be helpful guides in the management of
asthma.
This brings us to the following thera-
peutical issues: how can we optimize asthma
control? Are there other options, apart from
doubling the dose of ICS? Why is a combination
of ICS and long-acting b2-agonists (LABA) often
not ‘good enough’? We will discuss these topics
in the view of recent clinical studies in asthma
and will provide some useful background
information.Therapeutic options to optimize asthma
control
Doubling the dose of ICS
According to current guidelines, anti-inflammatory
therapy with ICS represents the cornerstone of the
treatment of persistent asthma.5,6 Indeed, ade-
quate (long-term) treatment with ICS has been
shown to effectively improve several markers of
airway inflammation, including asthma exacerba-
tion rates, exhaled NO, airway eosinophils
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Table 1 Anamnestic parameters related to in-
creased AHR/airway inflammation and loss of
asthma control.
Increase in asthma signs and symptoms following
exposure to (a)specific stimuli (e.g. weather
changes, cold, cigarette smoke, parfume,
allergens, etc)
Exercise-induced bronchoconstriction
Nightly awakenings due to worsening of asthma
Increased use of rescue bronchodilators
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almost all maintenance therapy, ICS may induce
both local (e.g. hoarseness, candida infections of
the laryngo-pharynx) and long-term use in high
daily doses (adults: 41000 mg/day; children:
4800 mg/day) even systemic side effects (e.g.
osteoporosis, cataracta lentis).13 Besides, even
high doses ICS could not completely abolish all
aspects of the airway inflammation in asthma.14,15
In accordance with these findings, two recent
studies failed to demonstrate the benefit of
doubling the dose of ICS on the exacerbations
rate in subjects with mild-to-moderate persistent
asthma.16,17 These long-term placebo-controlled
studies were performed in 290 and 390 patients,
respectively, with mild-to-moderate persistent
asthma, during 6 and 12 months, respectively.16,17
As compared to placebo, preventively doubling
the dose of ICS in patients at risk for an exacerba-
tion failed to affect the overall exacerbation rate
in both studies.16,17 Obviously, increasing the ICS
dose per se does not offer ultimate control for
every type of asthma. Hence, more potent com-
pounds or complementary treatment modalities are
needed.Table 2 LABA versus LTRA: most important
properties and effects.
Long-acting b2-agonists (LABA)
Inhaled formulation (local activity)
Long-acting, potent bronchodilation
No clinically relevant anti-inflammatory effects
Leukotriene receptor antagonists (LTRA)
Oral compounds (systemic activity)
Anti-inflammatory effects, complementary to
inhaled corticosteroids
Mild bronchodilator effects (as a result of anti-
inflammatory effects)Add-on therapies
The above-mentioned studies have lead to
the concept of achieving optimal asthma control
with the ‘lowest possible’ doses of ICS, applying
add-on therapy in the treatment steps 3 and
4.5,6 Presently, there are two main add-on options:
(1) LABA resulting in further improvement of
the airway function by potent bronchodilation
or (2) leukotriene receptor antagonists (LTRA)
offering complementary suppression of the air-
way inflammation (Table 2).5,6,18,19 Clinical and
pathophysiological implications of both add-on
options will be discussed.Add-on therapy with long-acting
b2-agonists
Most important findings from recent clinical
trials
In a multi-center study in 852 patients with mild-to-
moderate persistent asthma, adding a LABA (for-
moterol, 12 mg b.i.d.) to a lower ICS dose (budeso-
nide 100 mg b.i.d.) produced a similar improvement
in various asthma parameters including similar
reduction in mild exacerbations rate as the four-
fold higher ICS dose alone (budesonide 400 mg b.i.d;
average decrease of exacerbations of 40% and 37%,
respectively).18 However, the ultimate reduction in
exacerbation rate (by on average 62%) was
achieved by combining LABA (formoterol, 12 mg
b.i.d.) with the higher ICS dose (budesonide 400 mg
b.i.d).18 Other studies have confirmed these
data,20,21 including the so-called GOAL study. In
this recent multi-center study in patients with
mild-to-moderate persistent asthma, (near) total
asthma control was achieved adding the LABA
salmeterol to half the dose of ICS.22 Unfortunately,
no surrogate markers of inflammation have been
included in these or other similar studies with LABA
to provide substantial pathophysiological support
to the data.18,20–22
Mechanism of action
LABA are potent bronchodilators providing a quick,
long-lasting spasmolytic effect. Although there is
some evidence of reducing eosinophils and mast
cells in bronchial biopsies especially when added to
ICS,23,24 LABA do not seem to possess clinically
relevant anti-inflammatory properties per se
(Table 2). Despite 7 days pre-treatment with
salmeterol, no protective effects could be
demonstrated against allergen-induced airway
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addition, 6 weeks of treatment with this potent
bronchodilator, failed to provide any improvement
on parameters of airway inflammation, despite a
significant improvement in symptoms and lung
function in subjects with persistent asthma.26
Hence, LABA provide instant relief of symptoms
and improvement of lung function, but do not
affect the underlying airway inflammation. Hence,
early introduction of LABA may mask the airway
inflammation.Add-on therapy with leukotriene
receptor antagonists
Background information
Cysteinyl leukotrienes (cysLTs: LTC4, LTD4 and LTE4)
are bronchoactive mediators, that are released
within the airways following activation of asthma-
related inflammatory cells and that cannot be
blocked by corticosteroids.15 These mediators play
an important role in the inflammatory process of
asthma 27 and in associated allergic syndromes.28,29
Their effects are mediated through stimulation of
specific CysLT-receptors that have been demon-
strated within human airways.
Mechanism of action
In the 1980s, the anti-leukotrienes have been
developed. The first compounds of this novel class
of anti-asthma drugs have been worldwide regis-
tered in the second half of 1990s. The mechanism
of action of the LTRA is based on counteracting the
effects of cysLTs at their receptor site (CysLT1-
receptor) within the airways. This results in a dual
effect: (a) suppression of the airway inflammation
and as a result (b) mild bronchodilator properties
(Table 2).27,30 Both effects are superimposed on the
effects of ICS and short-acting b2-agonists, respec-
tively, underlining a different mechanism of ac-
tion.27,30 In several studies, LTRA have been shown
to improve symptoms and lung function para-
meters. Moreover, they have been shown to possess
bronchoprotective properties, reducing the AHR
and providing partial protections against airway-
narrowing stimuli including exercise, allergen and
aspirin.27,30 In addition, being oral compounds,
LTRA possess systemic activity, and hence suppress
the airway inflammation throughout the entire
airways, even beyond the reach of inhaled for-
mulae, including the upper and small airways. In
patients with allergic rhinitis (AR) (450% of theasthma patients suffer of AR), the combination of
LTRA and an H1-receptor antagonist was equally
effective as the golden standard therapy with
topical corticosteroids.31 There is now substantial
evidence of the beneficial (add-on) effects of
LTRA coming from many controlled clinical
trials; the most important ones will be discussed
subsequently.Clinical studies and controversies
Many studies have demonstrated improvements of
asthma control following addition of an LTRA to low
dose of ICS in both adults and children (manage-
ment step 2).32,33 Apart from improving symptoms
and lung function, add-on therapy with LTRA
particularly produced a significant reduction in
asthma exacerbations and inflammation para-
meters. In the so-called COMPACT-study (manage-
ment step 3), 12 weeks of treatment with a
moderate dose of ICS (budesonide 800 mg/day)
combined with the LTRA montelukast (1 10mg)
produced similar beneficial effects as doubling the
ICS dose (budesonide 1600 mg/dag).34 These bene-
ficial effects have been demonstrated on various
parameters of asthma, including symptoms, lung
function parameters, nightly awakenings, and the
frequency of exacerbations.34 Moreover, both
treatments have been shown to be safe, except
for a higher incidence of airway infections in the
budesonide 1600 mg arm.34 In another study in 581
patients with asthma, adding montelukast to the
existing dose of ICS, enabled 81% to taper off and
61% to discontinue the ICS without losing asthma
control.35 In a recent placebo-controlled study in
639 patients with mild to severe persistent asthma
(management steps 2–4), adding montelukast for
16 weeks reduced the exacerbation frequency by
on mean 35% irrespective of the ICS dose
(400–1600 mg/day).19 Conclusively, recent data
confirm and underscore the complementary anti-
inflammatory activity of LTRA in asthma.
However, there are also some studies that could
not demonstrate any (additive) effects of LTRA in
asthma.36–38 In the placebo-controlled study by
Robinson and colleagues, adding montelukast for 2
weeks to high doses of ICS/oral corticosteroids was
obviously too short to establish any additional
improvement in patients with moderate to severe
persistent asthma (management steps 3 and 4).36
Apart from the short treatment period in these
patients, the disputable study design (i.e. no
washout-period in a study testing anti-inflamma-
tory therapy) could also account for the negative
findings. These study bias have been reported in
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Fish and Nelson, respectively,37,38 which are in fact
identical, compared the bronchodilator effects of
the combination anti-inflammatory therapy/long-
acting bronchodilator (ICS/LABA) with that of a
combination of two anti-inflammatory compounds
(ICS/LTRA).37,38 Hence, taking into account the
mechanisms of action of all compounds tested, the
results of both studies could already be foretold,
especially in an asthmatic population with a
reversible lung function (reversibility412%). Inter-
esting, however, are the results of two other
studies comparing the effects of the same combi-
nations on different outcome parameters of asth-
ma.40,41 In the first study, both combinations
appeared equally effective in improving symptoms
and lung function in patients with mild-to-moder-
ate persistent asthma.40 However, the combination
ICS/LTRA showed superior effectiveness in suppres-
sing inflammation both within the airways and in
peripheral blood.40 Similar results were reported in
a study in 1490 patients with mild-to-moderate
persistent asthma in whom the effect of both
combinations during 48 weeks have been tested on
symptoms, lung function parameters, exacerbation
rate and peripheral eosinophils.41 Both combina-
tions showed similar effectiveness in preventing
asthma exacerbations. However, this appeared to
be achieved through different mechanisms of
action: ICS/LABA mainly improved symptoms and
lung function, whereas ICS/LTRA appeared superior
in suppressing features of inflammation.41Table 3 Adverse events related to LTRA.
Head ache
Gastro-intestinal dyscomfort
Thirst (in the ages of 2–5 years)Adverse events
Although in the past 8 years, LTRA have already
been prescribed to over 25 million patients with
asthma worldwide, including 6,4 million young
children, only few adverse events related to their
use have been reported. The majority of the
reported adverse events have been described as
‘mild’ and present as headache, gastro-intestinal
discomfort, and in the very young children as thirst
(Table 3). Rumours about a possible relationship
between LTRA and the occurrence of Churg-Strauss
Syndrome could be refuted. This syndrome has
been shown to become manifest in patients in
whom (very) high doses of (inhaled) corticosteroids
could be stopped while using LTRA.42 In all reported
cases, the Churg-Strauss Syndrome appeared to
be pre-existent and relapsed due to withdrawal
of the corticosteroids.42 As is the case with all
novel systemic therapy, we should always remain
alert towards potential new adverse events at all
times.What add-on therapy should be applied,
when and why?
In the past years, many studies and reports have
addressed the so-called therapeutic step (2)-3-
dilemma i.e. should we (first) add an LABA or an
LTRA to the ICS? The results of the most important
randomized clinical trials are summarized in
Table 4 and have been discussed previously. Given
the different mechanisms of action of LABA and
LTRA, the choice in fact means: ‘optimising the
lung function’ or ‘optimising the airway inflamma-
tion suppression’. It does not come as a surprise,
that the combination ICS/LABA mainly produces
complementary improvement of lung function,
whereas the combination ICS/LTRA predominantly
results in complementary suppression of inflamma-
tion. Table 5 summarizes the recommended use of
LTRA in asthma according to GINA5.Conclusions and recommendations
According to current guidelines, optimal treatment
of persistent asthma consists of adequate suppres-
sion of the airway inflammation.5,6 The ICS are the
cornerstone in the treatment of persistent asthma
in the lowest possible, effective dose.5,6 Based on
recent controlled studies in asthma, add-on ther-
apy to low/middle doses of ICS has proved to
be at least as effective as doubling the dose of ICS
(Table 5).18,41 Currently, there are two main
options for add-on therapy in steps (2)-4 in asthma:
LABA and ICS either separately or in one device, or
the combination of oral leukotriene receptor
antagonists (LTRA) and ICS.5,6 Although both com-
binations have produced comparable improvement
of various asthma parameters, including symptoms
and exacerbation rates, both combinations achieve
this in a different manner. While the combination
ICS/LABA focuses on improving the lung function,
ICS/LTRA’s main objective is complementary sup-
pression of the airway inflammation. These differ-
ences in effects result from a different mechanism
of action: bronchodilator versus bronchoprotective
cq. anti-inflammatory effect and local versus
systemic activity (Table 2).
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Table 5 Recommended use of LTRA in asthma
(adults and children) according to GINA.
Step 1: as monotherapy in mainly exercise-
induced bronchoconstriction
Step 2: add-on to low dose of ICS
Step 3: add-on to middle dose of ICS
Step 4: add-on to high dose of ICS
Table 4 Therapeutic step 3-dilemma: ICS/LABA versus ICS/LTRA.
Asthma severity Combination therapy Outcome parameters Best combination [References]
Mild-moder. ICS/LABA Symptom scores ICS/LABA [37]
Persistent (n ¼ 948) vs. ICS/LTRA Lung function ICS/LABA
Mild-moder. ICS/LABA Symptom scores ICS/LABA [38]
Persistent (n ¼ 447) vs. ICS/LTRA Lung function ICS/LABA
Mild-moder. ICSy/LABA Exacerbations Both [41]
Persistent (n ¼ 1490) vs. ICSy/LTRA Blood eosinophils ICS/LTRA
Symptom scores Both
Lung function ICS/LABA
Moderate ICSz/LABA symptom scores Both [40]
Persistent (n ¼ 20) vs. ICSz/LTRA Lung function Both
Airway inflammation ICS/LTRA
ICS, inhaled corticosteroids; LABA, long-acting b2-agonists; LTRA, leukotriene receptor agonists.
Doses ICS: low-middle doses ICS.
Doses ICS: low-high doses ICS.
yDoses ICS: low doses ICS.
zDoses ICS: low-middle doses ICS.
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add-on therapies, one needs to ask oneself the
following questions: First, ‘do I want to achieve a
better asthma control, and how will I do this?’ And
second, ‘is my primary goal complementary sup-
pression of the airway inflammation or do I mainly
aim for improving the lung function?’ Although in
the daily practice monitoring of the airway inflam-
mation/hyperresponsiveness is often impossible,
some anamnestic indices may provide a usuful
guide to adequate asthma control (Table 1).
Nevertheless, in patients with persistent asthma
in whom active airway inflammation is the main
issue, treatment should primarily focus on supres-
sing the airway inflammation, which implicates
that LTRA should be added to their ICS (Tables 2 and
4). These patients can be identified by their
increased airway responsiveness to (a)specific
irritants, increased asthma complaints during ex-
ercise, nightly awakenings, etc (Table 1). All these
complaints are suggestive of an increased airway
responsiveness caused by active airway inflamma-
tion. Should we first add a LABA, we will encountera considerable improvement of symptoms and lung
function that in fact will mask the underlying
airway inflammation. However, in some cases
(steps 3 and 4), optimal asthma control may be
achieved by combining all treatment modalities.
Future studies should confirm this option.Summary
Asthma is a chronic inflammatory disorder of the
airways. Hence, asthma management focuses on
suppressing the airway inflammation by (1) preven-
tion, i.e. avoiding a(specific) irritants and (2) anti-
inflammatory therapy. Inhaled corticosteroids (ICS)
are the cornerstone in the treatment of persistent
asthma, and the lowest possible, effective dose of
ICS should be applied. To this end, current guide-
lines advocate the use of add-on therapy in
management steps (2), 3 and 4. Currently, there
are 2 main options for add-on therapy: long-acting
b2-agonists (LABA) and leukotriene receptor an-
tagonists (LTRA), both having a different mechan-
ism of action. LABA come as an inhaled formula and
produce potent, longstanding bronchodilation
(without anti-inflammatory properties), while LTRA
are oral compounds, and hence act systemically,
possessing mainly anti-inflammatory effects. Based
on recent, controlled trials in asthma, we have
made an attempt to explain why optimising the
suppression of airway inflammation should precede
optimising the lung function in patients with
persistent asthma.
ARTICLE IN PRESS
Optimal control of airway inflammation in asthma 661References
1. Busse WW. Inflammation in asthma: the cornerstone of the
disease and target of therapy. J Allergy Clin Immunol
1998;102:S17–22.
2. Boulet LP. Physiopathology of airway hyperresponsiveness.
Curr Allergy Asthma Rep 2003;3:166–71.
3. Jeffery PK. Remodeling in asthma and chronic obstructive
lung disease. Am J Respir Crit Care Med 2001;164:S28–38.
4. McParland BE, Macklem PT, Pare PD. Airway wall remodel-
ing: friend or foe? J Appl Physiol 2003;95:426–34.
5. Global initiative for asthma: global strategy for asthma
management and prevention. NHBLI/WHO workshop, NIH
Publication; 1998, 2002.
6. British Thoracic Society guidelines for asthma. Thorax
2003;58(Suppl I):i1–i94.
7. Teeter JG, Bleecker ER. Relationship between airway
obstruction and respiratory symptoms in adult asthmatics.
Chest 1998;113:272–7.
8. Sont JK, Willems LN, Bel EH, et al. Clinical control and
histopathological outcome of asthma when using airway
hyperresponsiveness as an additional guide to long-term
treatment. The AMPUL study group. Am J Respir Crit Care
Med 1999;159:1043–51.
9. Green RH, Brightling CE, McKenna S, et al. Asthma
exacerbations and sputum eosinophil counts: a randomised
controlled trial. Lancet 2002;360:1715–21.
10. Bjermer L. History and future perspectives of treating
asthma as a systemic and small airways disease. Respir Med
2001;95:703–19.
11. Ward C, Pais M, Bish R, Reid D, Feltis B, Johns D, Walters EH.
Airway inflammation, basement membrane thickening and
bronchial hyperresponsiveness in asthma. Thorax 2002;57:
309–16.
12. Kharitonov SA, Barnes PJ. Nitric oxide in exhaled air is a new
marker of airway inflammation. Monaldi Arch Chest Dis
1996;51:533–7.
13. Allen DB, Bielory L, Derendorf H, Dluhy R, Colice GL, Szefler
SJ. Inhaled corticosteroids: past lessons and future issues. J
Allergy Clin Immunol 2003;112:S1–40.
14. Louis R, Lau LCK, Bron AO, Roldaan AC, Radermecker M,
Djukanovic R. The relationship between airways inflamma-
tion and asthma severity. Am J Resp Crit Care Med
2000;161:9–16.
15. Dworski R, Fitzgerald GA, Oates JA, et al. Effect of oral
prednisone on airway inflammatory mediators in atopic
asthma. Am J Respir Crit Care Med 1994;149:953–9.
16. FitzGerald JM, Becker A, Sears MR, Mink S, Chung K, Lee J.
Canadian asthma exacerbation study group. Doubling the
dose of budesonide versus maintenance treatment in asthma
exacerbations. Thorax 2004;59:550–6.
17. Harrison TW, Oborne J, Newton S, Tattersfield AE. Doubling
the dose of inhaled corticosteroid to prevent asthma
exacerbations: a randomised controlled trial. Lancet
2004;363:271–5.
18. Pauwels RA, Lo¨fdahl C-G, Postma DS, Tattersfield AE,
O0Byrne P, Barnes PJ, et al. Effect of inhaled formeterol
and budesonide on exacerbations of asthma. N Engl J Med
1997;337:1405–11.
19. Vaquerizo MJ, Casan P, Casatillo J, Perpina M, Sanchis J,
Sobradillo V, et al. Effect of montelukast added to inhaled
budesonide on control of mild to moderate asthma. Thorax
2003;58:204–10.
20. Lemanske RF, Sorkness CA, Mauger EA, Lazarus SC, Boushey
HA, Fahy JV, et al. Inhaled corticosteroid reduction andelimination in patients with persistent asthma receiving
salmeterol. J Am Med Assoc 2001;285:2594–603.
21. O’Byrne PM, Barnes PJ, Rodriquez-Roisin R, Runnerstrom E,
Sandstrom T, Svensson K, et al. Low dose inhaled budesonide
and formoterol in mild persistent asthma: the OPTIMA
randomized trial. Am J Respir Crit Care Med 2001;164:
1392–7.
22. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ,
Pauwels RA, et al. (GOAL Investigaters Group). Can guide-
line-defined asthma control be achieved? The Gaining
Optimal Asthma Control Study. AM J Respir Crit Care Med
2004;170(8):836–44.
23. Wallin A, Sandstrom T, Cioppa GD, Holgate S, Wilson S. The
effects of regular inhaled formoterol and budesonide on
preformed Th-2 cytokines in mild asthmatics. Respir Med
2002;96:1021–5.
24. Wallin A, Sue-Chu M, Bjermer L, et al. Effect of inhaled
fluticasone with and without salmeterol on airway
inflammation in asthma. J Allergy Clin Immunol 2003;
112:72–8.
25. Calhoun WJ, Hinton KL, Kratzenberg JJ. The effect of
salmeterol on markers of airway inflammation following
segmental allergen challenge. Am J Respir Crit Care Med
2001;163:881–6.
26. Roberts JA, Bradding P, Britten KM, et al. The long-
acting beta2-agonist salmeterol xinafoate: effects on
airway inflammation in asthma. Eur Respir J 1999;14:
275–82.
27. Diamant Z, Sampson AP. Anti-inflammatory mechanisms of
leukotriene modulators. Clin Exp Allergy 1999;29:1449–53.
28. Howarth PH. Leukotrienes in rhinitis. Am J Respir Crit Care
Med 2000;161:s133–6.
29. Fauler J, Neumann Ch, Tsikas D, et al. Enhanced synthesis of
cysteinyl leukotrienes in atopic dermatitis. Br J Dermatol
1993;128:627–30.
30. Sampson AP, Pizzichini E, Bisgaard H. Effect of cysteinyl
leukotrienes and leukotriene receptor antagonists on mar-
kers of inflammation. J Allergy Clin Immunol 2003;111:
S49–61.
31. Wilson AM, Orr LC, Sims EJ, et al. Antiasthmatic effects of
mediator blockade versus topical cotricosteroids in allergic
rhinitis and asthma. Am J Respir Crit Care Med 2000;
162:1297–301.
32. Laviolette M, Malmstrom K, Lu S, et al. Montelukast added
to inhaled beclomethasone in treatment of asthma. Am
J Respir Crit Care Med 1999;160:1862–8.
33. Simons FE, Villa JR, Lee BW, Teper AM, Lyttle B, Aristizabal
G, et al. Montelukast added to budesonide in children with
persistent asthma: a randomized, double-blind, crossover
study. J Pediatr 2001;138:694–8.
34. Price DB, Hernandez D, Magyar P, et al. Randomised
controlled trial of montelukast plus inhaled budesonide
versus double dose inhaled budesonide in adult patients with
asthma. Thorax 2003;58:211–6.
35. Price DB, Rouleau MY, Fletcher CP, et al. Use of montelukast
in tapering inhaled corticosteroid therapy: an open-label 48-
week trial. Curr Ther Res 2001;62:743–55.
36. Robinson DS, Campbell D, Barnes PJ. Addition of leukotriene
antagonists to therapy in chronic persistent asthma: a
randomised double-blind placebo-controlled trial. Lancet
2001;357:2001–11.
37. Fish JE, Israel E, Murray JJ, et al. Salmeterol powder
provides significantly better benefit than montelukast in
asthmatic patients receiving concomitant inhaled corticos-
teroid therapy. Chest 2001;120:423–30.
ARTICLE IN PRESS
Z. Diamant, T. van der Molen66238. Nelson HS, Busse WW, Kerwin E, et al. Fluticasone
propionate/salmeterol combination provides more effec-
tive asthma control than low-dose inhaled corticosteroid
plus montelukast. J Allergy Clin Immunol 2000;106:
1088–95.
39. Pavord ID, editor. Leukotriene antagonists and symptom
control in chronic persistent asthma. Editorial. Lancet
2001;357:1991–2.
40. Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ. Evaluation of
salmeterol or montelukast as second-line therapy for asthmanot controlled with inhaled corticosteroids. Chest 2001;
119:1021–6.
41. Bjermer L, Bisgaard H, Bousquet J, et al. Montelukast and
fluticasone compared with salmeterol and fluticasone in
protecting against asthma exacerbation in adults: one year,
double blind, randomised, comparative trial. Thorax
2003;327:891–5.
42. Kemp JP. Recent advances in the management of asthma
using leukotriene modifiers. Am J Respir Med 2003;2:
139–56.
